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10.3 m, P= 0.14). Response rate was 32.7% and 38.7% in women and 
men, respectively (P=0.4).
Conclusions: Based on this study the MOS was not statistically sig-
niﬁcant between women and men with advanced NSCLC treated with 
platinum based chemotherapy. Differences in pathologic subtype and 
mean age may translate this ﬁnding. To elucidate the impact of sex on 
MOS in patients with advanced NSCLC we need further well balanced 
studies. 
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Background: Docetaxel is a taxene anticancer drug with activity 
against a broad range of cancers. Pulmonary toxicity is a well-known 
complication observed with several anticancer drugs. But, interstitial 
pneumonitis as a toxicity of docetaxel is very rare.
Methods: A total of 53 patients with non-small cell lung cancer who 
received chemotherapy including docetaxel from January 2006 to 
December 2006 were analyzed retrospectively. 
Results: 9 out of 53 patients (17.0%) showed newly developed ground 
glass opacity with/without consolidation or reticular density on fol-
low up chest CT scans during docetaxel therapy. The lesions were 
not thought to be associated with disease progression or pulmonary 
infection. Majority of patients who showed newly developed abnormal 
CT ﬁndings consistent with interstitial pneumonitis had worsened or 
newly appeared dyspnea with deterioration of lung function of restric-
tive pattern. In association with the chemotherapy regimens, 7 out of 
9 patients with DIIP received weekly docetaxel (30-40mg/m2), and 
remaining 2 received non-weekly docetaxel(60-75mg/m2). Among 7 
patients who received weekly docetaxel, docetaxel only (30mg/m2) 
were 4, and docetaxel (40mg/m2) combined with cisplatin(35mg/m2) 
were 3. In association with the cumulative dose of docetaxel, below 
60mg/m2 was none, between 60 and 120 mg/m2 was 1, between 120 
and 240 mg/m2 were 4, and between 240 and 480mg/m2 were 4. The 
locations of abnormal radiographic ﬁndings were mainly peripheral (8 
out of 9) and upper lobe (7 out of 9). For the treatment of DIIP 4 out of 
9 patients received corticosteroid treatment, and all 4 patients showed 
symptomatic improvement. 
Conclusions: DIIP developed in increasing frequency as the cumula-
tive dose of docetaxel increased, especially with weekly regimen. 
Special concern should be given to the development of DIIP during 
docetaxel chemotherapy as its cumulative dose increases. DIIP should 
be included in differential diagnosis of newly developed radiographic 
abnormalities such as ground glass opacity or consolidation during 
docetaxel treatment especially if the lesion is peripheral and upper lobe 
predominant. For more clear clariﬁcation of DIIP, further prospective 
study of large scale is required.
P2-266 NSCLC: Cytotoxic Chemotherapy Posters, Tue, Sept 4  
A phase II study of the combination chemotherapy of Docetaxel 
and Carboplatin in advanced non-small cell lung cancer
Kim, Ji-Ho; Ahn, Young Mi; Roh, Yong Ho; Nam, Seung-Hyun; Kim, 
Bong-Seog 
Seoul Veterans Hospital, Seoul, Korea
Background: To evaluate the efﬁcacy and safety of induction chemo-
therapy with docetaxel and carboplatin in advanced lung cancer.
Methods: Between January 2005 and January 2007, 54 patients were 
enrolled and evaluable. Patients were treated with Docetaxel 75mg/m3 
and Carboplatin AUC 5 on day 1 every 21 days.
Result: The median age was 62 (range 23-79) years old. Among the 
54 patients, 51 were male. Pathologically, 19 patients had adenocar-
cinoma, 19 patients had squamous carcinoma and 3 patients had large 
cell carcinoma. Complete responses (CR) were in 2(3.7%) patients and 
partial responses (PR) in 26(48.14%) patients. The overall response 
rate was 51.85% and the median response duration was 5 (range, 1 to 
12.7) months. The median progression-free survival was 10.5 (range, 
1.4 to 19.5) months. The median overall survival for all patients was 
14.8 (range, 1.4 to 23.8) months.
During a total 253 cycles, anemia greater than CTC grade 2 occurred 
in 51 cycles(20.15%), leukopenia occurred in 22 cycles(8.69%) and 
thrombocytopenia occurred in 19 cycles(7.5%). Non-hematologic 
toxicities were minor and easily controlled.
Conclusion: The combination chemotherapy of docetaxel and carbo-
platin has moderate efﬁcacy with acceptable toxicities in patients with 
advanced NSCLC.
P2-267 NSCLC: Cytotoxic Chemotherapy Posters, Tue, Sept 4  
The efficacy and characteristics of palliative chemotherapy for 
elderly patients with advanced or recurrent non-small cell lung 
cancer
Kim, Tae Yong Kim, Jin Won Keam, Bhumsuk Kim, Yu Jung Kim, 
Sunyoung Han, Hye Suk Lee, Se-Hoon Kim, Dong-Wan Kim, Young 
Hwan Heo, Dae Seog 
Seoul National University Hospital, Seoul, Korea
Background: We conducted retrospective analysis to evaluate the efﬁ-
cacy and characteristics of palliative chemotherapy for elderly patients 
with advanced or recurrent non-small cell lung cancer(NSCLC).
Methods: Between Mar 2000 and Feb 2004, newly diagnosed chemo-
naïve patients with advanced or recurrent NSCLC were included. All 
patients were histologically or pathologically proven to be NSCLC, 
with performance status 0 to 2. Comorbidity was evaluated according 
to the Charlson’s comorbidity index. All patients received platinum-
based combination chemotherapy(containing paclitaxel or gemcitabine) 
as the ﬁrst-line treatment. The old age group was deﬁned as patients 
with 65 years or more of age.
Results: Total 404 patients were retrospectively analyzed. The number 
of patients in the young age and the old age group were 283(70%) and 
121(30%), respectively. The average number of total regimens(2.31 of 
old age vs. 2.81 of young age, respectively;p<0.001) and cycles(8.78 
vs. 10.69, p=0.006) per head were signiﬁcantly less in the old age 
group than in the young age group. Average administered doses of 
paclitaxel(119.3 vs. 137.4 mg/m2, p<0.001) and gemcitabine(1962.1 vs. 
2216.7 mg/m2, p<0.001) per cycle were lower in the old age group than 
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in the young age group. The ratio of dose reduction of the ﬁrst-cycle in 
initial chemotherapy were 14.8% in the young age group and 55.9% in 
the old age group(p<0.001). Despite lower dose-intensity of chemother-
apy, median overall survival of the old age group was similar to that of 
the young age group(12.6 vs. 13.9 months, p=0.3471). Among the old 
age group, the average of number of regimens(2.22 of elderly patients 
without comorbidity vs. 2.39 of those with comorbidity, respectively; 
p=0.454) and cycles(8.04 vs. 9.84, p=0.105) per head were similar 
between elderly patients without comorbidity and with comorbidity. 
There was no signiﬁcant difference in median overall survival between 
elderly patients without comorbidity and with comorbidity(11.2 vs 14.8 
months, p=0.3054). Elderly patients with dose-reduction of the ﬁrst-
cycle in the initial chemotherapy received signiﬁcantly less number of 
regimens(2.09 of elderly patients with dose-reduction vs. 2.62 of those 
without dose-reduction, p=0.017) and cycles of chemotherapy(7.79 vs. 
10.58, p=0.016) as compared with elderly patients without dose-reduc-
tion. Although elderly patients with dose-reduction received less num-
ber of regimens and cycles of chemotherapy, median overall survival 
of elderly patients with dose-reduction was equivalent to that of elderly 
patients without dose-reduction(11.2 vs. 14.8 months, p=0.0742).
Conclusions: Although signiﬁcantly lower dose-intensity of chemo-
therapies were conducted in elderly patients with advanced or recurrent 
NSCLC, the efﬁcacy and survival of elderly patients were similar to 
those of young patients. The optimal dose and schedule of palliative 
chemotherapy for elderly patients with advanced or recurrent NSCLC 
should be redeﬁned.
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Background: During anti-cancer chemotherapy for lung cancer and 
other various malignancies, some patients suffer due to sudden onset of 
dyspnea and acute respiratory failure with acute lung injury, diagnosed 
by chest CT and clinical ﬁndings. It is difﬁcult to make an immediate 
differential diagnosis of chemotherapy induced acute lung injury and 
other causes of acute lung injury, such as respiratory infection or sepsis.
Methods: We analyzed the clinical and laboratory characteristics, 
causative chemotherapeutic drugs, treatment responses of suspicious 
chemotherapeutic drug induced acute lung injury retrospectively.
Results: Fourteen patients with lung cancer and two cases of other 
cancer (esophageal and breast cancer) were included. The probable 
causative chemotherapeutic drugs were geﬁtinib (5 cases), docetaxel 
(5 cases), paclitaxel (1 case), navelbine (2 cases), gemcitabine (1 case), 
epirubicin (1 case), and etoposide (1 case). The most frequent radio-
lographic ﬁnding was ground glass attenuation detected in chest CT. 
Most of the patents were treated with broad spectrum antibiotics and 
steroid (methylprednisolone 125-250mg bid intravenously for 2-5 days 
or prednisolone 0.5-1mg/kg/day for 1-2 weeks) and mechanical ventila-
tion if needed. Twelve patients were survived, but 3 patients died due 
to reparatory failure and accompanied complications. The APACHE II 
score was high in non-survivors (23) compared to survivors (14.5). The 
patients with combined respiratory infection conﬁrmed by microbio-
logical studies showed unfavorable treatment response. The patients 
with more severe initial respiratory dysfunction requiring mechanical 
ventilatory supports showed poor prognosis.
Conclusion: It is important to make an early diagnosis and early 
initiation of treatment for acute lung injury associated with anti-cancer 
chemotherapy.
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Background: RRM1 is related to the resistance for gemcitabine che-
motherapy in patients who revealed high RRM1 expression in tumor 
tissues. This study was designed under the hypothesis that the poly-
morphism in RRM1 promoter, which regulate RRM1 gene expression, 
could impact on the result of the therapeutic response and the prognosis 
of the patients with lung cancer treated with gemcitabine.
Methods: A retrospective data set of 97 patients with advanced 
NSCLC treated with gemcitabine as the ﬁrst-line chemotherapy was 
studied. Allelotyping of RRM1 gene was performed with real-time 
PCR and sequencing using genomic DNA achieved from peripheral 
white blood cells.
Results: The frequencies of RRM1 gene promoter allelotypes were 
RR37CC-R524TT in 58, RR37AC-RR524CT in 29, and others in 
10. The response rate for gemcitabine containing chemotherapy was 
49.5%. When the author analyzed the therapeutic responses according 
to RRM1 promoter allelotypes, 65.5% in RR37AC-RR524CT group 
and 43.1% in RR37CC-RR524TT group (P = 0.049). There were no 
statistically signiﬁcant differences in overall survival and progression 
free survival by the two allelotypes. 
Conclusions: The response rate was higher in the patients’ group 
with RR37AC-RR524CT in which we expected to show lower level 
of RRM1 gene expression than in the patients’ group with RR37CC-
RR524TT, and that result was thought to correspond to our hypothesis. 
If further studies would verify and supplement the result of our study, 
we can expect to improve the prognosis of the advanced non-small cell 
lung cancer through the application of our result for the patient-tailored 
therapy.
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